Publication

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia

Wu, S., Dai, Y., Zhang, Y., Wang, X., Wang, L., Ma, D., Zhang, L., Pang, Y., Jiao, Y., Niu, M., Xu, K., Ke, X., Shi, J., Cheng, Z. & Fu, L., Aug-2018, In : Cancer Gene Therapy. 25, 7-8, p. 207-213 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Sun Wu
  • Yifeng Dai
  • Yuan Zhang
  • Xiufeng Wang
  • Lihua Wang
  • Dong Ma
  • Lingxiu Zhang
  • Yifan Pang
  • Yang Jiao
  • Mingshan Niu
  • Kailin Xu
  • Xiaoyan Ke
  • Jinlong Shi
  • Zhiheng Cheng
  • Lin Fu

The mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML, are unclear. In order to explore the prognostic significance of the mutational spectrum in IR-AML, 106 IR-AML patients were collected from The Cancer Genome Atlas database. Sixty-two patients underwent chemotherapy-only, forty-four proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fifty-five patients had more than five recurrent genetic mutations. NPM1 had the highest mutation frequency, followed by DNMT3A, FLT3, RUNX1, IDH2, IDH1, and TET2. In all patients, allo-HSCT was an independent favorable factor for EFS and OS (P = 0.036, P = 0.001, respectively); age >= 60 years, FLT3-ITD and mutations in DNMT3A and RUNX1 were independent risk factors for survival (all P <0.05). In the chemotherapy-only group, multivariate analysis showed that age 60 years was an independent risk factor for EFS and OS (P = 0.008, P = 0.017, respectively). In the allo-HSCT group, multivariate analysis indicated that MLL-PTD was an independent risk fact for EFS (P = 0.037), FLT3-ITD and RUNX1 mutations independently contributed to poor OS (P = 0.035, P = 0.014, respectively). In conclusion, older age was an important risk factor for IR-AML patients undergoing chemotherapy-only; FLT3-ITD, MLL-PTD and RUNX1 mutations were significant risk factors for IR-AML patients who received allo-HSCT.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalCancer Gene Therapy
Volume25
Issue number7-8
Publication statusPublished - Aug-2018

    Keywords

  • HEMATOPOIETIC-CELL TRANSPLANTATION, ACUTE MYELOGENOUS LEUKEMIA, EUROPEAN LEUKEMIANET, CHEMOTHERAPY, MANAGEMENT, EXPRESSION, REMISSION, AML

View graph of relations

ID: 75784648